Clinical trials: Induction of Birth
Induction of Labour
REgistry of MisOprostol 200 µg Vaginal dElivery System
The design of the study is post-marketing, observational, multi-centre and open-label. The study does not provide treatment; only patients to whom misoprostol 200 µg vaginal delivery system (VDS) is prescribed may be included.
- Trial name
- REMOVE (NCT02242214)
- Testing
- Misoprostol
- Where
- Netherlands
- Volunteers
- 106 people
- Sponsor
- Ferring Pharmaceuticals
Induction of Labor Affected Fetus / Newborn
An RCT of a Synthetic Osmotic Cervical Dilator for Induction of Labour in Comparison to Dinoprostone Vaginal insErt
Induction of labour (where labour is started artificially) is traditionally carried out with a range of different drugs or by surgery (rupturing the membranes or 'waters').
- Trial name
- SOLVE (NCT03001661)
- Testing
- Dilapan-S, Dinoprostone
- Where
- United Kingdom
- Volunteers
- 674 people, healthy volunteers welcome
- Sponsor
- Birmingham Women's NHS Foundation Trust
Preterm Birth, Premature
Comparison of the Acute Effects of Chest Physiotherapy Methods Applied in Different Positions in Preterm Newborns
Infants in the neonatal intensive care unit (NICU) may be lost due to risks such as being sensitive, frequent exposure to birth complications and being prone to infection.
- Conditions
- Preterm Birth, Premature, Bronchopulmonary Dysplasia, Respiratory Distress Syndrome
- Trial name
- therapy (NCT05036603)
- Testing
- chest physiotherapy
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Sanko University
BPD - Bronchopulmonary Dysplasia
Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stem Cell(MSC) Transplantation in the Treatment of Bronchopulmonary Dysplasia(BPD) in Premature Infants
Bronchopulmonary dysplasia (BPD) is a chronic lung disease, which is a major complication of very low and ultra-low preterm infants.
- Trial name
- MSC，BPD (NCT06788470)
- Testing
- MSC
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Preterm Infant, Respiratory Insufficiency Syndrome of Newborn
Non-invasive Respiratory Support in Preterm Infants
Lungs of babies born early are not fully developed and they often need a machine to help them breathe. The traditional approach to provide this support is with a breathing tube passed into the windpipe.
- Conditions
- Preterm Infant, Respiratory Insufficiency Syndrome of Newborn, Bronchopulmonary Dysplasia
- Trial name
- NOVEL (NCT03512158)
- Testing
- Non-invasive respiratory support mode
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- McMaster Children's Hospital
Birth Asphyxia
Asphyxia Associated Metabolite Biomarker Investigation 2
Follow-up of participants of AAMBI1 study at age of at least 2 years. AAMBI1(ClinicalTrials.gov ID: NCT03354208): Verification of biomarkers in a human population for their ability to diagnose the severity of neonatal asphyxia.
- Trial name
- AAMBI2 (NCT04714502)
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 144 people
- Sponsor
- InfanDx AG
Respiratory Distress Syndrome, Newborn, Premature Birth
SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.
SURFAXIN® (lucinactant) treatment will be examined in very low birth weight infants to prevent development of chronic lung disease, commonly known as bronchopulmonary dysplasia (BPD), in premature infants who have required…
- Conditions
- Respiratory Distress Syndrome, Newborn, Premature Birth, Bronchopulmonary Dysplasia
- Trial name
- NCT00215540
- Testing
- Lucinactant 175 mg/kg, Lucinactant 90 mg/kg
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Windtree Therapeutics
Chemotherapy-induced Nausea and Vomiting
Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)
The purpose of this study was to determine the appropriate dosing regimen of fosaprepitant, when administered with ondansetron (with or without dexamethasone), for the prevention of CINV in children from birth to <17 years of…
- Trial name
- NCT01697579
- Testing
- Fosaprepitant, Ondansetron, 5-hydroxytryptamine 3 antagonist
- Volunteers
- 240 people
- Sponsor
- Merck Sharp & Dohme LLC
Neonatal Oxygen Desaturation, Premature
Non-Invasive Neurally Adjusted Ventilatory Assist (NAVA) Prone vs Supine in Premature Infants
This research study is being done to investigate the effect of changing an infant's body position on how hard the baby works to breathe, the baby's oxygen level, the baby's carbon dioxide level, the baby's lung volume, the baby's…
- Conditions
- Neonatal Oxygen Desaturation, Premature, Ventilator Lung; Newborn, Apnea of Prematurity
- Trial name
- NCT05968586
- Testing
- Body positioning
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Milton S. Hershey Medical Center
Induction of Labor
Induction of Labor With a Foley Balloon Catheter: Inflation With 30ml Compared to 60ml
The rate of labor induction is rising throughout the United States for a variety of reasons. Medical conditions that lead to increased risk of prolonging the pregnancy to both mother and fetus are not infrequent.
- Trial name
- NCT00451308
- Testing
- Induction of labor with foley balloon - 60cc of saline, Induction of labor with foley balloon with 30cc
- Where
- United States
- Volunteers
- 192 people
- Sponsor
- University of California, San Francisco
Preterm Birth, Bronchopulmonary Dysplasia
Improving Prematurity-Related Respiratory Outcomes at Vanderbilt
The goal of IMPROV is to identify molecular mechanisms that contribute to lung injury and long-term breathing problems in preterm infants by investigating two interrelated biochemical pathways: the urea cycle-nitric oxide pathway…
- Conditions
- Preterm Birth, Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity
- Trial name
- IMPROV (NCT01460576)
- Where
- 2 sites in United States
- Volunteers
- 253 people
- Sponsor
- Vanderbilt University Medical Center
Bronchopulmonary Dysplasia
Phase 1 Intravenous Citrulline for the Prevention of Bronchopulmonary Dysplasia in Preterm Infants
Premature infants are at risk for developing bronchopulmonary dysplasia (BPD). L-citrulline may decrease that risk, but we do not know the safety or dose of this drug for use in premature babies.
- Trial name
- NCT00742534
- Testing
- Intravenous L-Citrulline
- Where
- United States
- Sponsor
- Vanderbilt University
Transient Tachypnea of Newborn and Fetal Acidosis
Impact Of Maternal Spinal Anesthesia-Induced Hypotension At Scheduled Cesarean Delivery On Risk Development Of Transient Tachypnea Of Newborn And Fetal Acidosis
We will evaluate the association between transient tachypnea of newborns and fetal acidosis development to the degree and duration of maternal hypotension and anesthesia to delivery time during spinal anesthesia at scheduled…
- Trial name
- NCT06383624
- Where
- Egypt
- Volunteers
- 115 people
- Sponsor
- Benha University
Patent Ductus Arteriosus
Closure of Patent Ductus Arteriosus With Indomethacin or Ibuprofen in Extreme Low Birth Weight Infants
Pharmacological closure of ductus arteriosus with prostaglandin (PG) inhibitors has been used for years. Previous studies indicated that ibuprofen has similar effect on ductal closure as indomethacin but has less adverse effects…
- Trial name
- NCT01758913
- Testing
- Ibuprofen
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Taipei Medical University Hospital
Lung Function, BPD - Bronchopulmonary Dysplasia
Early-life MRI Biomarkers of Longer-term Respiratory Morbidity in Infants Born Extremely Preterm (EMBLEM)
Bronchopulmonary dysplasia (BPD) is a common, major complication of premature birth, associated with developmental and health consequences that continue into adulthood.
- Trial name
- EMBLEM (NCT06065215)
- Testing
- Magnetic Resonance Imaging (MRI), Echocardiogram, Lung ultrasound
- Where
- 4 sites in Canada
- Volunteers
- 319 people
- Sponsor
- Children's Hospital of Eastern Ontario
Pregnancy
Relevance of Ultrasound Screening for Foetal Macrosomia
Management of fetal macrosomia is based on a suspicion of macrosomia (no certainty before birth). This management is an artificial induction of labour for an earlier delivery and therefore a lower fetal weight gain.
- Trial name
- USmacro (NCT04443205)
- Testing
- Data record
- Where
- France
- Volunteers
- 3,000 people
- Sponsor
- CHU de Reims
Infant, Newborn, Infant, Low Birth Weight
Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome
The purpose of this study is to compare the efficacy of two surfactants, Exosurf Neonatal (Burroughs Wellcome Co.) and Survanta (Ross Laboratories), for the treatment of neonatal respiratory distress syndrome.
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
- Trial name
- Surfactant 1 (NCT01203358)
- Testing
- Exosurf, Survanta
- Where
- 13 sites in United States
- Volunteers
- 617 people
- Sponsor
- NICHD Neonatal Research Network
Ureaplasma Infections
Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants
The purpose of this study is to determine whether intravenous azithromycin is effective in eradicating Ureaplasma respiratory tract infection in preterm infants born at 24 to 28 weeks gestation.
- Trial name
- AZIPIII (NCT01778634)
- Testing
- Azithromycin
- Where
- 7 sites in United States
- Volunteers
- 121 people
- Sponsor
- University of Maryland, Baltimore
Leukoplakia, Periodontal Disease
Randomized, Double Blind, Placebo-Controlled, Phase IIB Trial of Ketorolac Mouth Rinse Evaluating the Effect of Cyclooxygenase Inhibition on Oropharyngeal Leukoplakia: Collaborative Study of the NCI, NIDCD and the NIDCR
In Phase II trials, treatment with ketorolac tromethamine oral rinse has been shown to block periodontal disease progression even in the absence of standard clinical intervention such as scaling and root planing which is…
- Trial name
- NCT00001698
- Testing
- Ketorolac Rinse
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Habitual Abortion
Low Molecular Weight Heparin and/or Aspirin in Prevention of Habitual Abortion
1 % of all pregnancies end in habitual/recurrent abortion. In about half of women with habitual abortions (HAB) hereditary or acquired (antiphospholipid antibodies) thrombophilia are observed.
- Trial name
- HABENOX (NCT00959621)
- Testing
- Aspirin, Klexane, Klexane and ASA
- Where
- Finland
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- University of Helsinki